RxDoctor Payments Data

Angela Rodriguez

Optometrist · Appleton, WINPI 1770870602

Payments from drug & device makers

$3,805in general payments, 2019–2025

Across 184 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$534
  • Bausch & Lomb Americas Inc.$515
  • AbbVie$477
  • Kala Pharmaceuticals, Inc.$347
  • Oyster Point Pharma, Inc.$290
  • Coopervision Inc.$278
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,805 in reported general payments places this provider in the 90th percentile of 867 optometrist providers in Wisconsin.

See all optometrist providers in Wisconsin

Medicare billing

Part B allowed, 2024
$43,717
Medicare patients
230
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine179$188,102
XiidraLifitegrast113$116,782
Cyclosporine64$25,642
MieboPerfluorohexyloctane/Pf29$22,172
LumiganBimatoprost19$13,966
CequaCyclosporine16$13,607
TyrvayaVarenicline Tartrate13$12,426
VyzultaLatanoprostene Bunod26$9,155
CombiganBrimonidine Tartrate/Timolol11$6,677
Loteprednol Etabonate39$6,089
Alphagan PBrimonidine Tartrate15$4,602
Fluorometholone62$4,476
RocklatanNetarsudil Mesylat/Latanoprost11$4,429
Lotemax SmLoteprednol Etabonate13$3,468
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$3,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$477$213,348224 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$515$148,109168 claims
Sun Pharmaceutical Industries Inc.Cequa$266$13,60716 claims
Oyster Point Pharma, Inc.Tyrvaya$290$12,42613 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm$155$9,55852 claims
AlconSimbrinza$181$2,68611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 867 optometrist providers in Wisconsin.

Other optometrist in Appleton

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →